- Home
- SHOE vs CABA Comparison
SHOE vs CABA Comparison
Compare SHOE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOE | CABA |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.3M | 339.1M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHOE | CABA |
|---|---|---|
| Price | $14.03 | $1.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 789.0K | ★ 5.0M |
| Earning Date | 11-19-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,135,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $661.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.18 | $1.39 |
| 52 Week High | $16.29 | $4.23 |
Technical Indicators
Market Signals| Indicator | SHOE | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 29.40 |
| Support Level | $14.00 | N/A |
| Resistance Level | $16.00 | $2.14 |
| Average True Range (ATR) | 0.52 | 0.14 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 87.40 | 14.70 |
Price Performance
Historical ComparisonAbout SHOE Shoe Station Group Inc. Common Stock
Shoe Station Group Inc is a one-stop family footwear destination that offers an impressive selection from top brands. It is a fashion destination for footwear, southern-inspired accessories, and apparel. The group has physical stores throughout five Southern states and is available online at ShoeStation.com, shipping all across the U.S. Its offer products for Women's, Men's, and Kids.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.